secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0000875045-23-000005
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q4 2022 rev $2.54B; GAAP EPS $3.79; guides FY2023 Non-GAAP EPS $15-$16
-----------------------------------------------------------------------------

- Q4 revenue $2,544M, GAAP EPS $3.79, Non-GAAP EPS $4.05.
- FY2022 revenue $10,173M (-7% YoY); GAAP EPS $20.87; Non-GAAP EPS $17.67 (-8% YoY).
- FY2023 guidance: mid-single digit revenue decline; Non-GAAP EPS $15.00-$16.00.
- LEQEMBI (lecanemab) granted FDA accelerated approval; traditional filing submitted in US, EU, Japan, China.
- Zuranolone NDA for MDD/PPD accepted with Priority Review; PDUFA date August 5, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/0000875045-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/biib-20230215.htm
  HTML page:      https://secwatch.observer/filing/0000875045-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer